Venn Life Sciences expands into France with acquisition of DCI
9 Nov 2010
Dublin-based Venn Life Sciences has acquired Paris-based
clinical research organisation DCI. DCI offers clinical trial management
services for Phase I-IV and contract placement solutions for clinical
research projects.
“It is an exciting day for Venn,” said Tony Richardson, Venn’s
CEO. “We are constantly seeking to improve what we offer to our
sponsors both in geographic reach and scale of services. This
addition to our group extends our operations throughout Europe,
enhancing an already extensive breadth of expertise in therapeutic
indications and clinical trial management services".
The acquisition is a key milestone for Venn in its objective to
become a leading international player, offering sponsors increased
access to principal investigators and patient pools worldwide. A
major focus area for Venn is local on the ground regulatory
knowledge especially in Europe which has long been a complex area
for drug development organisations.
DCI brings extensive knowledge of the French clinical trial
industry. With over 20 years' experience DCI counts some of the
world’s leading pharmaceutical and biotech companies among its
clients.
“The pace of growth at Venn sees us joining a company at a very
exciting time and being part of Venn will enable us to better
leverage our expertise offering our local clients access to
international sites and personnel with worldwide experience of
clinical trial management,” said Frédérique Cabrières, founder of
DCI. "Both company’s business ethic is focused on a commitment to
excellence and quality and this can only be reinforced by the coming
together of the two organisations."